The risk of endophthalmitis following intravitreal triamcinolone injection in the DRCRnet and SCORE clinical trials
- PMID: 17765429
- PMCID: PMC2065757
- DOI: 10.1016/j.ajo.2007.04.011
The risk of endophthalmitis following intravitreal triamcinolone injection in the DRCRnet and SCORE clinical trials
Abstract
Purpose: To report the incidence of endophthalmitis following intravitreal injection using a standardized injection procedure.
Design: Two randomized clinical trials.
Methods: Nonpreserved intravitreal triamcinolone acetonide in prefilled syringes (Allergan, Inc, Irvine, California, USA) was injected intravitreally in the Diabetic Retinopathy Clinical Research Network (DRCR net) and the Standard Care vs COrticosteroid for REtinal Vein Occlusion (SCORE) clinical trials. The standardized injection procedure did not include the use of topical antibiotics during the days prior to the injection.
Results: As of December 31, 2006, 1,378 intravitreal injections (538 eyes) have been administered in the Diabetic Retinopathy Clinical Research Network Diabetic Macular Edema trial and 631 injections (301 eyes) in Standard Care vs COrticosteroid for REtinal Vein Occlusion. There was one case of endophthalmitis in the 2,009 injections to date (0.05%, 95% confidence interval 0.001% to 0.277%).
Conclusion: A low rate of endophthalmitis is achievable using a standardized procedure for intravitreal injection without prescribing antibiotic prophylaxis on the days prior to the injection.
Trial registration: ClinicalTrials.gov NCT00105027 NCT00336323.
Similar articles
-
Risk of endophthalmitis after intravitreal drug injection when topical antibiotics are not required: the diabetic retinopathy clinical research network laser-ranibizumab-triamcinolone clinical trials.Arch Ophthalmol. 2009 Dec;127(12):1581-3. doi: 10.1001/archophthalmol.2009.304. Arch Ophthalmol. 2009. PMID: 20008710 Free PMC article. Clinical Trial.
-
Incidence of endophthalmitis and use of antibiotic prophylaxis after intravitreal injections.Ophthalmology. 2012 Aug;119(8):1609-14. doi: 10.1016/j.ophtha.2012.02.014. Epub 2012 Apr 4. Ophthalmology. 2012. PMID: 22480743
-
Noninfectious endophthalmitis associated with intravitreal triamcinolone injection.Arch Ophthalmol. 2003 Sep;121(9):1279-82. doi: 10.1001/archopht.121.9.1279. Arch Ophthalmol. 2003. PMID: 12963610
-
[Intravitreal triamcinolone acetonide for the treatment of intraocular edematous and neovascular diseases].Ophthalmologe. 2004 Feb;101(2):113-20. doi: 10.1007/s00347-003-0982-0. Ophthalmologe. 2004. PMID: 14991306 Review. German.
-
Intravitreal triamcinolone acetonide for treatment of intraocular oedematous and neovascular diseases.Acta Ophthalmol Scand. 2005 Dec;83(6):645-63. doi: 10.1111/j.1600-0420.2005.00592.x. Acta Ophthalmol Scand. 2005. PMID: 16396641 Review.
Cited by
-
Topical azithromycin or ofloxacin for endophthalmitis prophylaxis after intravitreal injection.Clin Ophthalmol. 2012;6:1595-9. doi: 10.2147/OPTH.S35795. Epub 2012 Oct 9. Clin Ophthalmol. 2012. PMID: 23109798 Free PMC article.
-
Comparison of the efficacy and safety of drug therapies for macular edema secondary to central retinal vein occlusion.BMJ Open. 2018 Dec 28;8(12):e022700. doi: 10.1136/bmjopen-2018-022700. BMJ Open. 2018. PMID: 30593547 Free PMC article.
-
The Association between Intravitreal Steroids and Post-Injection Endophthalmitis Rates.Ophthalmology. 2015 Nov;122(11):2311-2315.e1. doi: 10.1016/j.ophtha.2015.07.005. Epub 2015 Aug 15. Ophthalmology. 2015. PMID: 26281823 Free PMC article.
-
Drug treatment of macular oedema secondary to central retinal vein occlusion: a network meta-analysis.BMJ Open. 2014 Jul 23;4(7):e005292. doi: 10.1136/bmjopen-2014-005292. BMJ Open. 2014. PMID: 25056974 Free PMC article.
-
A European perspective on topical ophthalmic antibiotics: current and evolving options.Ophthalmol Eye Dis. 2011 Oct 24;3:29-43. doi: 10.4137/OED.S4866. Print 2011. Ophthalmol Eye Dis. 2011. PMID: 23861622 Free PMC article.
References
-
- Scott IU, Flynn HW., Jr Reducing the risk of endophthalmitis following intravitreal injections. Retina. 2007;27:10–12. - PubMed
-
- Speaker MG, Menikoff JA. Prophylaxis of endophthalmitis with topical povidone-iodine. Ophthalmology. 1991;98:1769–1775. - PubMed
-
- Ta CN, Egbert PR, Singh K, et al. Prospective randomized comparison of 3-day versus 1-hour preoperative ofloxacin prophylaxis for cataract surgery. Ophthalmology. 2002;109:2036–2041. - PubMed
-
- Isenberg SJ, Apt L, Yoshimori R, et al. Chemical preparation of the eye in ophthalmic surgery. IV. Comparison of povidone-iodine on the conjunctiva with a prophylactic antibiotic. Arch Ophthalmol. 1985;103:1340–1342. - PubMed
-
- Gragoudas ES, Adamis AP, Cunningham ET, et al. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med. 2004;351:2805–2816. - PubMed
Publication types
MeSH terms
Substances
Associated data
Grants and funding
- EY14229/EY/NEI NIH HHS/United States
- 5U10EY014352-05/EY/NEI NIH HHS/United States
- EY14231/EY/NEI NIH HHS/United States
- EY14269/EY/NEI NIH HHS/United States
- U10 EY023529/EY/NEI NIH HHS/United States
- U10 EY014351/EY/NEI NIH HHS/United States
- U10 EY023207/EY/NEI NIH HHS/United States
- U10 EY014229/EY/NEI NIH HHS/United States
- 5U10EY014351-05/EY/NEI NIH HHS/United States
- U10 EY014404/EY/NEI NIH HHS/United States
- UG1 EY014231/EY/NEI NIH HHS/United States
- U10 EY014231/EY/NEI NIH HHS/United States
- U10 EY014269/EY/NEI NIH HHS/United States
- 5U10EY014404-05/EY/NEI NIH HHS/United States
- U10 EY014352/EY/NEI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Medical
Research Materials